AusCann experiences medicinal hashish canine trial outcomes promising | The Examiner

News, Local News, Medical Cannabis, Dogs, Pain Relief, AusCann, CannPaul, Tasmania, USA, Study

There is hope for painful boobs, limping Labradoodles and fighting Shih Tzus. A Tasmania-affiliated company has reported promising results from a US study of a cannabis-based pain reliever for dogs. Perth-based AusCann Group Holdings Limited, which sources cannabis resin from Tasmanian alkaloids, announced that its acquisition of CannPal Animal Therapeutics has been moved from pilot production to a commercial manufacturing partner to create ingredients for animal health product development using MicroMAX technology. “The veterinary pain and inflammation market is valued at over $ 1 billion worldwide. There is a need for viable treatment alternatives for dogs, particularly older and vulnerable dogs who are currently receiving treatments for pain and inflammation because of their potential adverse side effect profiles can be undesirable or ineffective, “said AusCann. With MicroMAX, microscopic oil droplets are encapsulated in special foods. AusCann said the results of the U.S. veterinary and owner evaluation study supported the use of the CPAT-01 product for pain, lameness, and better quality of life in dogs owned by customers diagnosed with osteoarthritis. “The positive indicators for CPAT-01 to improve pain, inflammation and mood based on clinical and biochemical results give the company the confidence to advance the development program for CPAT-01,” said AusCann. Forty-six dogs completed treatment during the trial, with vets and physical exams assessed for lameness at zero, 28 and 56 days. AusCann said that all dogs treated with CPAT-01 showed significant improvement. The dogs that had placebo treatments had poorer mobility after 56 days. The company said the study results would help shape the design of its development program. AusCann had begun again to work towards a meeting with the U.S. Food and Drug Administration and the Center for Veterinary Medicine. This would allow AusCann to share data from the study and receive guidance on the US development and regulatory plan.

/images/transform/v1/crop/frm/storypad-hRgnU7CfAjJBjZ9k7qBUYH/ee3cf0e8-a8e9-4f96-b975-15e2a70e8999.jpg/r3_3_1198_678_w1200_h678_fmax

There is hope for painful boobs, limping Labradoodles and fighting Shih Tzus.

A Tasmania-affiliated company has reported promising results from a US study of a cannabis-based pain reliever for dogs.

Perth-based AusCann Group Holdings Limited, which sources cannabis resin from Tasmanian alkaloids, announced that its acquisition of CannPal Animal Therapeutics has been moved from pilot production to a commercial manufacturing partner to use MicroMAX technology to create ingredients for animal health product development.

“The veterinary pain and inflammation market is valued at over $ 1 billion worldwide. There is a need for viable treatment alternatives for dogs, particularly older and vulnerable dogs who are currently receiving treatments for pain and inflammation due to their potential adverse side effect profiles can be undesirable or ineffective, “said AusCann.

With MicroMAX, microscopic oil droplets are encapsulated in special foods.

AusCann said the results of the U.S. veterinary and owner evaluation study supported the use of the CPAT-01 product for pain, lameness, and better quality of life in dogs owned by customers diagnosed with osteoarthritis.

“The positive indicators for CPAT-01 to improve pain, inflammation and mood based on clinical and biochemical results give the company the confidence to advance the development program for CPAT-01,” said AusCann.

Forty-six dogs completed treatment during the trial, with vets and physical exams assessed for lameness at zero, 28 and 56 days.

AusCann said that all dogs treated with CPAT-01 showed significant improvement.

The dogs that had placebo treatments had poorer mobility after 56 days.

The company said the study results would help shape the design of its development program.

AusCann had begun again to work towards a meeting with the U.S. Food and Drug Administration and the Center for Veterinary Medicine.

This would allow AusCann to share data from the study and receive guidance on the US development and regulatory plan.